Efficacy and tolerability of once-daily telithromycin compared with high-dose amoxicillin for treatment of community-acquired pneumonia

Infection

Volumn 30, Issue 6, 2002, Pages 378-386

  Hagberg, Lars ^a   Torres, A ^b   Van Rensburg, D ^d   Leroy, B ^c   Rangaraju, M ^c   Ruuth, E ^c  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^b Sanatorio 9 de Julio   (Argentina)

^c SANOFI   (France)

^d NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; TELITHROMYCIN;

ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; BACTEREMIA; BACTERIAL STRAIN; BACTERIUM ISOLATION; CLINICAL TRIAL; COMMUNITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CONVALESCENCE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG RESPONSE; ERADICATION THERAPY; FEMALE; HAEMOPHILUS INFLUENZAE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL DOCUMENTATION; MORAXELLA CATARRHALIS; MULTICENTER STUDY; NONHUMAN; RADIOLOGY; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIA; STREPTOCOCCUS PNEUMONIAE; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AMOXICILLIN; ANTI-BACTERIAL AGENTS; COMMUNITY-ACQUIRED INFECTIONS; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; KETOLIDES; MACROLIDES; MALE; MIDDLE AGED; PNEUMONIA, BACTERIAL;

EID: 0036452858     PISSN: 03008126     EISSN: None     Source Type: Journal    
DOI: 10.1007/s15010-002-2096-z     Document Type: Article

References (44)

1. Bartlett JG, Dowell SF, Mandell LA, File TM, Musher DM, Fine MJ: Practice guidelines for the management of community-acquired pneumonia in adults. Clin Infect Dis 2000; 31: 347-382.
2. Guest JF, Morris A: Community-acquired pneumonia: The annual cost to the National Health Service in the UK. Eur Respir J 1997; 10: 1530-1534.
3. Garau J: Changing patterns of etiology and resistance in community-acquired respiratory tract infections. Infect Dis Clin Pract 1998; 7 (suppl 2): 92-95.
4. Felmingham D, Grüneberg RN: The Alexander Project 1996-1997: Latest susceptibility data from this international study of bacterial pathogens from community-acquired lower respiratory tract infections. J Antimicrob Chemother 2000; 45: 191-203.
5. Reid R, Bradley JS, Hindler J.: Pneumococcal meningitis during therapy of otitis media with clarithromycin. Ped Infect Dis J 1995; 14: 1104-1105.
6. Jackson MA, Burry VF, Olson LC, Duthie SE, Kearns GL: Breakthrough sepsis in macrolide-resistant pneumococcal infection. Ped Infect Dis J 1996; 15: 1049-1051.
7. Ball P: Therapy for pneumococcal infection at the millennium: Doubts and certainties. Am J Med 1999; 107: 77-85.
8. Garau J, Lonks JR, Gomez L, Xeravins M, Medeiros AA: Failure of macrolide therapy in patients with bacteremia due to macrolide resistant Streptococcus pneumoniae [abstr]. In: Program of the 5th International Conference on the Macrolides, Azalides, Streptogramins, Ketolides and Oxazolidinones, 26-28 January 2000, Seville, Spain.
9. Kelley MA, Weber DJ, Gilligan P, Cohen MS: Breakthrough pneumococcal bacteremia in patients being treated with azithromycin and clarithromycin. Clin Infect Dis 2001; 31: 1008-1011.
10. Metlay JP, Hofmann J, Cetron MS, Fine MJ, Farley MM, Whitney C, Breiman RF: Impact of penicillin susceptibility on medical outcomes for adult patients with bacteremic pneumococcal pneumonia. Clin Infect Dis 2000; 30: 520-528.
11. Waterer GW, Wunderink RG, Jones CB: Fatal pneumococcal pneumonia attributed to macrolide resistance and azithromycin monotherapy. Chest 2000; 118: 1839-1840.
12. Barman Balfour JA, Figgitt DP: Telithromycin. Drugs 2001; 61: 815-829.
13. Barry AL, Fuchs PC, Brown SD: Antipneumococcal activities of a ketolide (HMR 3647), a streptogramin (quinupristin-dalfopristin), a macrolide (erythromycin), and a lincosamide (clindamycin). Antimicrob Agents Chemother 1998; 42: 945-946.
14. Bébéar CM, Renaudin H, Bryskier A, Bébéar C: Activity of telithromycin (HMR 3647), a new ketolide antimicrobial, against human mycoplasmas [abstr]. In: Program of the 5th International Conference on the Macrolides, Azalides, Streptogramins, Ketolides and Oxazolidinones, 26-28 January 2000, Seville, Spain.
15. Dubois J, St-Pierre C: In vitro study of the minimal inhibitory concentrations (MIC) of telithromycin (HMR 3647), macrolides and quinolones against Haemophilus, Streptococcus, Staphylococcus and Moraxella strains obtained from upper and lower respiratory tract infections and from maxillary sinus aspiration [abstr]. In: Abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, 17-20 September 2000, Toronto, Canada. Washington DC: American Society for Microbiology 2000.
16. Pankuch GA, Visalli MA, Jacobs MR, Appelbaum PC: Susceptibilities of penicillin- and erythromycin-susceptible and -resistant pneumococci to HMR 3647 (RU 66647), a new ketolide, compared with susceptibilities to 17 other agents. Antimicrob Agents Chemother 1998; 42: 624-630.
17. Pankuch GA, Hoellman DB, Lin G, Bajaksouzian S, Jacobs MR, Appelbaum PC: Activity of HMR 3647 compared to those of five agents against Haemophilus influenzae and Moraxella catarrhalis by MIC determination and time-kill assay. Antimicrob Agents Chemother 1998; 42: 3032-3034.
18. Reinert RR, Bryskier A, Lutticken R: In vitro activities of the new ketolide antibiotics HMR 3004 and HMR 3647 against Streptococcus pneumoniae in Germany. Antimicrob Agents Chemother 1998; 42: 1509-1511.
19. Roblin PM, Hammerschlag MR: In vitro activity of a new ketolide antibiotic, HMR 3647, against Chlamydia pneumoniae. Antimicrob Agents Chemother 1998; 42: 1515-1516.
20. Schülin T,Wennersten CB, Moellering RC, Eliopoulous GM: In vitro activity of the new ketolide antibiotic HMR 3647 against gram-positive bacteria. J Antimicrob Chemother 1998; 42: 297-301.
21. Khair OA, Andrews JM, Honeybourne D, Jevons G, Vacheron F, Wise R: Lung concentrations of telithromycin after oral dosing. J Antimicrob Chemother 2001; 47: 837-840.
22. Lenfant B, Sultan E,Wable C, Pascual MH, Meyer BH, Scholtz HE: Pharmacokinetics of 800 mg once-daily oral dosing of the ketolide, HMR 3647, in healthy young volunteers [abstr]. In: Abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, 24-27 September 1998, San Diego, USA. Washington DC: American Society for Microbiology, 1998.
23. Fine MJ, Auble TE, Yealy DM, Hanusa BH, Weissfeld LA, Singer DE, Coley CM, Marrie TJ, Kapoor WN: A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997; 336: 243-250.
24. Hammerschlag MR: Community-acquired pneumonia due to atypical organisms in adults: Diagnosis and treatment. Infect Dis Clin Pract 1999; 8: 232-240.
25. American Thoracic Society: Guidelines for the management of adults with community-acquired pneumonia: Diagnosis, assessment of severity, antimicrobial therapy and prevention. Am J Respir Crit Care Med 2001; 163: 1730-1754.
26. British Thoracic Society: Standards of Care Committee: BTS guidelines for the management of community-acquired pneumonia in adults. Thorax 2001; 56: IV1-64.
27. Bartlett JG, Dowell SF, Mandell LA, File TM jr, Musher DM, Fine MJ: Guidelines from the Infectious Diseases Society of America. Practice guidelines for the management of community-acquired pneumonia in adults. Clin Infect Dis 2000, 31: 347-382.
28. Heffelfinger JD, Dowell SF, Jorgensen JH, Klugman KP, Mabry LR, Musher DM, Plouffe JF, Rakowsky A, Schuchat A, Whitney CG: Management of community-acquired pneumonia in the era of pneumococcal resistance. A report from the Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group. Arch Intern Med 2000; 160: 1399-1408.
29. Chen DK, McGeer A, de Azavedo JC, Low DE, for the Canadian Bacterial Surveillance Network: Decreases susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. N Engl J Med 1999; 341: 233-239.
30. Ferraro MJ, Brown S, Harding I: Prevalence of fluoroquinolone resistace amongst Streptococcus pneumoniae isolated in the United States during the winter of 2000-01 [abstr]. In: Abstracts of the 42 nd Interscience Conference on Antimicrobial Agents and Chemotherapy, 27-30 September 2002, San Diego, CA, USA. Washington DC: American Society for Microbiology, 2002.
31. Andersen G, Esmonde TS, Coles S, Macklin J, Carnegie C: A comparative safety and efficacy study of clarithromycin and erythromycin stearate in community-acquired pneumonia. J Antimicrob Chemother 1991; 27 (suppl A): 117-124.
32. File TM Jr, Segreti J, Dunbar L, Player R, Kohler R, Williams RR, Kojak C, Rubin A: A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in treatment of adults with community-acquired pneumonia. Antimicrob Agents Chemother 1997; 41: 1965-1972.
33. Genné D, Siegrist HH, Humair L, Janin-Jaquat B, de Torrenté A: Clarithromycin versus amoxicillin-clavulanic acid in the treatment of community-acquired pneumonia. Eur J Clin Microbiol Infect Dis 1997; 16: 783-788.
34. Léophonte P, Veyssier P: [Levofloxacin in the treatment of community-acquired pneumococcal pneumonia]. Presse Med 1999; 28: 1975-1979 (in French).
35. Lode H, Garau J, Grassi C, Hosie J, Huchon G, Legakis N, Segev S, Wijnands G: Treatment of community-acquired pneumonia: A randomized comparison of sparfloxacin, amoxycillin-clavulanic acid and erythromycin. Eur Respir J 1995; 8: 1999-2007.
36. Ramirez J, Unowsky J, Talbot GH, Zhang H, Townsend L: Sparfloxacin versus clarithromycin in the treatment of community-acquired pneumonia. Clin Ther 1999; 21: 103-117.
37. Carbon C, Moola S, Velancsics I, Leroy B, Rangaraju M, Decosta P: Efficacy of telithromycin, a new once-daily ketolide antibiotic, in the treatment of community-acquired pneumonia. Clin Microbiol Infect, in press.
38. Pullman J, Champlin J, Leroy B, Sidarous E: Oral telithromycin (HMR 3647) 800 mg once daily for 7-10 days is well tolerated and as effective as oral trovafloxacin 200 mg once daily in community-acquired pneumonia (CAP) [abstr]. In: Abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, 17-20 September 2000, Toronto, Canada. Washington DC: American Society for Microbiology, 2000.
39. Dunbar LM, Hassman J,Tellier G: Efficacy and tolerability of once-daily oral therapy with telithromycin compared with clarithromycin for the treatment of community-acquired pneumonia (CAP) in adults. J Am Board Fam Pract, in press.
40. Moola S, Hagberg L, Churchyard GA, Dyelewski JS, Sedani S, Staley H: A multicenter study of grepafloxacin and clarithromycin in the treatment of patients with community-acquired pneumonia. Chest 1999; 116: 974-983.
41. Leroy B, Rangaraju M: Highin vitro susceptibility of the ketolide telithromycin (HMR 3647) in clinical isolates of key respiratory pathogens [abstr]. In: Abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, 17-20 September 2000, Toronto, Canada. Washington DC: American Society for Microbiology, 2000.
42. Muller-Serieys C, Soler P, Cantalloube C, Lemaitre F, Gia HP, Brunner F, Andremont A: Bronchopulmonary disposition of the ketolide antimicrobial telithromycin (HMR 3647). Antimicrob Agents Chemother 2001; 45: 3104-3108.
43. Trémolières F, de Kock F, Daniel PR: Trovafloxacin versus high-dose amoxicillin (1 g three times daily) in the treatment of community-acquired bacterial pneumonia. Eur J Clin Microbiol Infect Dis 1998; 17: 447-453.
44. Finch RG, Woodhead MA: Practical considerations and guidelines for the management of community-acquired pneumonia. Drugs 1998; 55: 31-45.